Mineralys Therapeutics M&A Deal with Tanabe Pharma Corporation
Mineralys Therapeutics entered into a Termination Agreement and Payment Obligation Agreement with Tanabe Pharma Corporation to acquire full ownership of the intellectual property for lorundrostat. The agreements terminate the existing license and assign the patents and know-how directly to Mineralys, while maintaining existing commercial milestone obligations of up to $265 million. This transition from licensee to owner removes potential change-of-control payment triggers and consolidates the company's control over its lead drug candidate.
- Counterparty
- Tanabe Pharma Corporation